The Fly

EC authorizes new low-dose of Gilead’s Biktarvy to treat HIV in children

Gilead Sciences announced that the European Commission EC has authorized a new low-dose tablet dosage form of Biktarvy or bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets, and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg. The European Marketing Authorization is the first pediatric approval for Biktarvy in the European Union EU and applies to all 27 member states of the EU, as well as Norway, Iceland and Liechtenstein. "The European Commission’s approval is a significant milestone to address what is sadly an important unmet need, namely children with HIV requiring new treatment options," said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. "Additional therapy choices help to ensure children can access care and expand their HIV treatment options, which helps advance the collective efforts to overcome the HIV epidemic. Through the Gilead Global Pediatric Center of Excellence, we are committed to applying our decades of antiviral expertise to drive innovation in pediatric HIV research."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on GILD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More